Table 4 Liquid biopsy in clinical trials of GC.
From: Liquid biopsy in gastric cancer: predictive and prognostic biomarkers
Identifier | Disease | Intervention | Purpose | Country |
|---|---|---|---|---|
NCT04253106 | Hereditary Diffuse Gastric Cancer | plasma and gastric fluid genetic profiles | Diagnosis | France |
NCT04943406 | Gastric Cancer/Gastric Adenocarcinoma | plasma and peritoneal lavage ctDNA | Prognosis | Italy |
NCT05029869 | Gastric Cancer | plasma ctDNA | Prognosis | Vietnam |
NCT03957564 | Gastric Cancer/Gastro-esophageal Junction Cancer | plasma CTC, ctDNA and cfDNA | Prognosis and response to neoadjuvant chemotherapy | China |
NCT04385316 | Gastric Cancer | plasma ctDNA | Diagnosis | China |
NCT02610218 | Advanced/Metastatic Gastric Cancer | plasma CTC and cfDNA | Prognosis and response to targeted therapy | China |
NCT04665687 | Early Gastric Cancer | plasma ctDNA | Prognosis and diagnosis | Korea |
NCT05027347 | Early Gastric Cancer | plasma ctDNA | Prognosis | Vietnam |
NCT04000425 | Gastric Cancer | plasma ctDNA | Prognosis and response to adjuvant chemotherapy | China |
NCT04817826 | Gastric Cancer | plasma ctDNA | Prognosis and response to neoadjuvant immunotherapy | Italy |
NCT04484636 | Gastric Cancer | plasma ctDNA | Response to immunotherapy | Germany |
NCT03409848 | Gastric Cancer | plasma ctDNA | Response to immunotherapy | Germany |
